Answers are grounded in this paper and cite their sources.
This systematic review reveals digoxin's potential to decrease tumor volume in preclinical models, suggesting further investigation is needed.
This systematic review and meta-analysis was aimed to synthesize existing preclinical evidence on digoxin's anti-tumor effects via HIF-1α inhibition. This study was conducted as per PRISMA 2020 guidelines. A systematic literature search was conducted using PubMed/Medline, EMBASE, and Google Scholar, and based on the inclusion and exclusion criteria, a total of 13 studies were selected. The meta-analysis performed on the included studies revealed that the digoxin treatment decreased the tumor volume (IV:-1.40(-1.89 to -0.91) at 95% CI, p<0.00001, I 2 =42%), H I F-1α (IV:-2.43(-4.07 to -0.78) at 95% CI, p=0.004, I 2 = 62%), VEGF (IV:-1.14(-1.91 to -0.36) at 95% CI, p=0.004, I 2 = 0%), and GLUT-1 (IV: 1.57(-2.57 to -0.57) at 95% CI, p=0.002 I 2 = 0%), but had no statistically significant reduction in the tumor weight (IV:-0.31(-0.69 to 0.07), 95% CI, p=0.11, I 2 =98%), and CD31 marker (IV:-1.15(-3.10 to 0.79) at 95% CI, p=0.25, I 2 =71%) and has no effect on the animal survival rate (IV:6.46(-0.93 to 13.86) at 95% CI, p=0.09, I 2 =86%) compared to the control. Conclusions: In summary, the available moderate weight of evidence suggests that digoxin possesses potential anti-tumor effects via HIF-1α pathways. However, considering the pitfalls associated with the existing studies, there is a scope for conducting more robust pre-clinical studies. Further, randomized controlled trials in humans are essential to evaluate and validate the antitumor effect of digoxin. • Meta-analysis shows digoxin reduces tumor growth in preclinical models • Digoxin targets hypoxia inducible factor (HIF-1α) driving tumor growth pathways • Associated with reduced tumor size and key signals linked to growth • No consistent effect on survival or tumor weight across studies • Further preclinical studies and human trials are needed for validation
No takes yet. Share an insight, caveat, or question.
Bolar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: